• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

偏头痛的分层护理与阶梯式护理策略:护理策略中的残疾情况(DISC)研究:一项随机试验。

Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial.

作者信息

Lipton R B, Stewart W F, Stone A M, Láinez M J, Sawyer J P

机构信息

Innovative Medical Research Inc, 1200 High Ridge Rd, Stamford, CT 06905, USA.

出版信息

JAMA. 2000;284(20):2599-605. doi: 10.1001/jama.284.20.2599.

DOI:10.1001/jama.284.20.2599
PMID:11086366
Abstract

CONTEXT

Various guidelines recommend different strategies for selecting and sequencing acute treatments for migraine. In step care, treatment is escalated after first-line medications fail. In stratified care, initial treatment is based on measurement of the severity of illness or other factors. These strategies for migraine have not been rigorously evaluated.

OBJECTIVE

To compare the clinical benefits of 3 strategies: stratified care, step care within attacks, and step care across attacks, among patients with migraine.

DESIGN AND SETTING

Randomized, controlled, parallel-group clinical trial conducted by the Disability in Strategies Study group from December 1997 to March 1999 in 88 clinical centers in 13 countries.

PATIENTS

A total of 835 adult migraine patients with a Migraine Disability Assessment Scale (MIDAS) grade of II, III, or IV were analyzed as the efficacy population; the safety analysis included 930 patients.

INTERVENTIONS

Patients were randomly assigned to receive (1) stratified care (n = 279), in which patients with MIDAS grade II treated up to 6 attacks with aspirin, 800 to 1000 mg, plus metoclopramide, 10 mg, and patients with MIDAS grade III and IV treated up to 6 attacks with zolmitriptan, 2.5 mg; (2) step care across attacks (n = 271), in which initial treatment was with aspirin, 800 to 1000 mg, plus metoclopramide, 10 mg. Patients not responding in at least 2 of the first 3 attacks switched to zolmitriptan, 2.5 mg, to treat the remaining 3 attacks; and (3) step care within attacks (n = 285), in which initial treatment for all attacks was with aspirin, 800 to 1000 mg, plus metoclopramide, 20 mg. Patients not responding to treatment after 2 hours in each attack escalated treatment to zolmitriptan, 2.5 mg.

MAIN OUTCOME MEASURES

Headache response, achieved if pain intensity was reduced from severe or moderate at baseline to mild or no pain at 2 hours; and disability time per treated attack at 4 hours for all 6 attacks, compared among the 3 groups.

RESULTS

Headache response at 2 hours was significantly greater across 6 attacks in the stratified care treatment group (52.7%) than in either the step care across attacks group (40.6%; P<.001) or the step care within attacks group (36.4%; P<.001). Disability time (6 attacks) was significantly lower in the stratified care group (mean area under the curve [AUC], 185.0 mm. h) than in the step care across attacks group (mean AUC, 209.4 mm. h; P<.001) or the step care within attacks group (mean AUC, 199.7 mm. h; P<.001). The incidence of adverse events was higher in the stratified care group (321 events) vs both step care groups (159 events in across-attack group; 217 in within-attack group), although most events were of mild-to-moderate intensity.

CONCLUSION

Our results indicate that as a treatment strategy, stratified care provides significantly better clinical outcomes than step care strategies within or across attacks as measured by headache response and disability time. JAMA. 2000;284:2599-2605.

摘要

背景

各种指南推荐了不同的偏头痛急性治疗选择和用药顺序策略。在阶梯式治疗中,一线药物治疗失败后治疗方案逐步升级。在分层治疗中,初始治疗基于疾病严重程度或其他因素的评估。这些偏头痛治疗策略尚未得到严格评估。

目的

比较分层治疗、发作期内阶梯式治疗和发作期间阶梯式治疗这三种策略对偏头痛患者的临床疗效。

设计与地点

1997年12月至1999年3月,由残疾策略研究小组在13个国家的88个临床中心进行的随机、对照、平行组临床试验。

患者

共835例偏头痛成年患者纳入疗效分析人群,偏头痛残疾评估量表(MIDAS)评分为II、III或IV级;安全性分析纳入930例患者。

干预措施

患者被随机分配接受:(1)分层治疗(n = 279),MIDAS评分为II级的患者使用阿司匹林800至1000 mg加甲氧氯普胺10 mg治疗最多6次发作,MIDAS评分为III级和IV级的患者使用佐米曲普坦2.5 mg治疗最多6次发作;(2)发作期间阶梯式治疗(n = 271),初始治疗使用阿司匹林800至1000 mg加甲氧氯普胺10 mg。在前3次发作中至少对2次治疗无反应的患者改用佐米曲普坦2.5 mg治疗剩余3次发作;(3)发作期内阶梯式治疗(n = 285),所有发作的初始治疗均使用阿司匹林800至1000 mg加甲氧氯普胺20 mg。每次发作2小时后治疗无反应的患者将治疗升级为佐米曲普坦2.5 mg。

主要观察指标

头痛缓解情况,即疼痛强度从基线时的重度或中度降至2小时时的轻度或无痛;以及比较三组中所有6次发作在4小时时每次治疗发作的残疾时间。

结果

分层治疗组6次发作后2小时的头痛缓解率(52.7%)显著高于发作期间阶梯式治疗组(40.6%;P <.001)和发作期内阶梯式治疗组(36.4%;P <.001)。分层治疗组的残疾时间(6次发作)显著低于发作期间阶梯式治疗组(平均曲线下面积[AUC],209.4 mm·h;P <.001)和发作期内阶梯式治疗组(平均AUC,199.7 mm·h;P <.001)。分层治疗组的不良事件发生率高于两个阶梯式治疗组(发作期间阶梯式治疗组159例事件;发作期内阶梯式治疗组217例事件),分层治疗组有321例事件,尽管大多数事件为轻至中度。

结论

我们的结果表明,作为一种治疗策略,分层治疗在头痛缓解和残疾时间方面提供的临床结果显著优于发作期内或发作期间的阶梯式治疗策略。《美国医学会杂志》。2000年;284:2599 - 2605。

相似文献

1
Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial.偏头痛的分层护理与阶梯式护理策略:护理策略中的残疾情况(DISC)研究:一项随机试验。
JAMA. 2000;284(20):2599-605. doi: 10.1001/jama.284.20.2599.
2
Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study.偏头痛急性治疗分层护理与阶梯式护理策略的成本效益分析:护理策略中的残疾(DISC)研究
Pharmacoeconomics. 2002;20(2):91-100. doi: 10.2165/00019053-200220020-00002.
3
Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.佐米曲普坦鼻喷雾剂在长期偏头痛治疗试验中的耐受性及疗效一致性
CNS Drugs. 2003;17(11):839-51. doi: 10.2165/00023210-200317110-00005.
4
Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine.佐米曲普坦口服片剂用于月经性偏头痛急性治疗的疗效及耐受性
CNS Drugs. 2006;20(12):1019-26. doi: 10.2165/00023210-200620120-00005.
5
Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study.佐米曲普坦与乙酰水杨酸和甲氧氯普胺联合用药用于偏头痛急性口服治疗的比较:一项双盲、随机、三次发作的研究。
Eur Neurol. 2002;47(2):88-98. doi: 10.1159/000047959.
6
Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.佐米曲普坦鼻喷雾剂在偏头痛急性治疗中的起效速度和疗效:一项与佐米曲普坦片剂对比的随机、双盲、安慰剂对照、剂量范围研究
CNS Drugs. 2003;17(9):653-67. doi: 10.2165/00023210-200317090-00005.
7
Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study.佐米曲普坦鼻喷雾剂急性治疗偏头痛的起效速度、疗效及耐受性:一项随机、双盲、安慰剂对照研究
CNS Drugs. 2005;19(2):125-36. doi: 10.2165/00023210-200519020-00003.
8
The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group.口服佐米曲普坦(佐米格,311C90)用于偏头痛急性治疗的长期耐受性和疗效。一项国际研究。国际311C90长期研究组。
Headache. 1998 Mar;38(3):173-83.
9
The cost effectiveness of stratified care in the management of migraine.
Pharmacoeconomics. 2001;19(8):819-29. doi: 10.2165/00019053-200119080-00004.
10
Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial.2.5毫克口腔崩解片佐米曲普坦急性治疗偏头痛的无痛率:一项大型双盲安慰剂对照试验的结果
Curr Med Res Opin. 2005 Mar;21(3):381-9. doi: 10.1185/030079905x28926.

引用本文的文献

1
Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial.接受扎韦潘坦治疗的患者疼痛和功能障碍随时间的减轻:BHV3500 - 301 三期随机对照试验的事后分析
J Headache Pain. 2025 Jan 2;26(1):1. doi: 10.1186/s10194-024-01915-y.
2
Treatment Patterns and Persistence Among Patients Newly Diagnosed With Migraine in South Korea: A Retrospective Analysis of Health Claims Data.韩国新诊断偏头痛患者的治疗模式与持续治疗情况:健康保险理赔数据的回顾性分析
J Clin Neurol. 2024 Sep;20(5):529-536. doi: 10.3988/jcn.2023.0485.
3
Efficacy of Lasmiditan as a Secondary Treatment for Migraine Attacks after Unsuccessful Treatment with a Triptan.
在使用曲坦类药物治疗偏头痛发作失败后,拉米地坦作为二线治疗药物的疗效。
Neurol Int. 2024 Jun 7;16(3):643-652. doi: 10.3390/neurolint16030048.
4
Headaches in adults in supplementary health: management.补充健康保险中成人头痛的管理
Rev Assoc Med Bras (1992). 2024 Mar 15;70(1):e023D701. doi: 10.1590/1806-9282.023D701. eCollection 2024.
5
Acute Treatment of Migraine: Expert Consensus Statements from the United Arab Emirates (UAE).偏头痛的急性治疗:来自阿拉伯联合酋长国(UAE)的专家共识声明。
Neurol Ther. 2024 Apr;13(2):257-281. doi: 10.1007/s40120-023-00576-4. Epub 2024 Jan 19.
6
Migraine Management in Community Pharmacies: Knowledge, Attitude and Practice Patterns of Pharmacists in Saudi Arabia.沙特阿拉伯社区药房的偏头痛管理:药剂师的知识、态度和实践模式
Pharmacy (Basel). 2023 Sep 24;11(5):155. doi: 10.3390/pharmacy11050155.
7
Intravascular laser irradiation of blood as novel migraine treatment: an observational study.血管内激光血液辐照治疗偏头痛:一项观察性研究。
Eur J Med Res. 2023 Oct 25;28(1):457. doi: 10.1186/s40001-023-01438-3.
8
Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis.鼻腔给药治疗偏头痛急性发作的疗效和安全性:系统评价和网络荟萃分析。
J Headache Pain. 2023 Sep 18;24(1):129. doi: 10.1186/s10194-023-01662-6.
9
Pharmacological Management of Orofacial Pain.口腔颌面部疼痛的药物治疗管理。
Drugs. 2023 Sep;83(14):1269-1292. doi: 10.1007/s40265-023-01927-z. Epub 2023 Aug 26.
10
Revisiting Migraine: The Evolving Pathophysiology and the Expanding Management Armamentarium.重新审视偏头痛:不断演变的病理生理学与不断扩充的治疗手段
Cureus. 2023 Feb 2;15(2):e34553. doi: 10.7759/cureus.34553. eCollection 2023 Feb.